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doi:10.1016/j.jfma.2012.01.010Background/Purpose: Urinary tract infection (UTI) is the most common type of infectious
complication among kidney transplant patients. However, the antibiotic susceptibility of caus-
ative microorganisms and risk factors for concomitant bacteremia and recurrent infection are
rarely discussed.
Methods: This was a retrospective cohort review of kidney transplant recipients who had
received follow-up in the past 10 years at the Chung-Shan Medical University (Taichung,
Taiwan). Only community-acquired and symptomatic UTIs were included in this study.
Results: During the 5322 months of follow-up, 99 patients developed 167 episodes of UTI.
Forty-two (25%) episodes had concomitant bacteremia. Escherichia coli was the most common
causative microorganism, and strains with resistance to multiple commonly used empirical
antibiotics began to emerge. The independent risk factors for UTI with concomitant bacter-
emia in multivariate analysis were immunosuppression with tacrolimus (adjusted odds ratio
[AOR] 3.17; 95% confidence interval [CI] 1.29e7.75; PZ 0.011) and baseline serum creatinine
level >1.3 mg/dL before first UTI (AOR 2.55; 95% CI 1.02e6.36; P Z 0.045). However, there
were no factors that were significantly associated with recurrent infection.
Conclusion: From this study, we found that E coli tends to have resistance to commonly used
empirical antibiotics in this modern era and that patients who use the immunosuppressant
tacrolimus and have baseline serum creatinine level >1.3 mg/dL before their first UTI have
a tendency to suffer from concomitant bacteremia and even sepsis.
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methods and BBL Crystal Enteric/NF 4.0 identification kitsUrinary tract infection (UTI) is the most common type of
infectious complication among kidney transplant patients.1,2
Until recently, UTI has been considered to be a benign
medical illness in renal transplant patients; however, some
of the more recent reports have revealed that UTI seems
to increase the risk of subsequent graft dysfunction and
patient mortality.3e5 In particular, when progressing to
bacteremia or even sepsis, UTI always indicates a poor
prognosis and higher mortality rates.6e8 On the other hand,
with the frequent use of antibiotics in this modern era, the
rising antibiotic resistance rate of causative microorgan-
isms is also a serious concern.9 Thus, the goal of our study
was to characterize antibiotic susceptibility with regards
to causative microorganisms in the modern era and to
determine the risk factors for concomitant bacteremia or
recurrent infection in renal transplant recipients so as to
provide more timely and appropriate treatment.
Patients and methods
We performed a retrospective cohort review of renal
transplant recipients who had received follow-up in the
past 10 years at the Chung-Shan Medical University (a total
of nearly 650 patients) after the Institutional Research
Board approved this study. Standard three-combined
maintenance immunosuppressants including calcineurin
inhibitor (cyclosporine or tacrolimus), mycophenolate
mofetil and corticosteroids were administered to all
patients. The supplementary use of sirolimus was deter-
mined by the transplant team on an individual basis. All
patients received antibiotic prophylaxis with first-
generation cephalosporin intravenously for the first 3 days
after surgery and postoperative antibiotic prophylaxis with
trimethoprim-sulfamethoxazole during the first 6 months to
prevent Pneumocystis jirovecii pneumonia. A UTI was
diagnosed based on the presence of one of the following
signs or symptoms: fever, urgency, frequency, dysuria, or
suprapubic tenderness, together with a positive urine
culture (>10,0000 colony forming units of a pathogenic
microorganism per mL of urine).10 We also included
episodes with typical clinical symptoms and consistent
urinalysis but that had a negative culture result if the
symptoms resolved after antibiotic therapy was adminis-
tered. We only included community-acquired UTIs, which
was defined as onset of infection before hospital admission
and not within 10 days of hospital discharge and excluded
asymptomatic bacteriuria from the scheduled follow-up
examinations.11 Recurrent infection was defined as at
least two symptomatic UTIs in the interval of 12 months.12
Urological evaluations, including renal sonography, urody-
namic study and prostate examination, were carried out for
these patients to evaluate whether they had any anatom-
ical or functional abnormalities.
The methods for identification of the bacteria causing
UTI and antibiotic sensitivity tests were as follows. Clean-
catch urine samples taken from patients were inoculated
onto 5% blood agar and Eosin-Methylene Blue (EMB) agar
with 0.01 mL calibrated loops by a semi-quantitative
technique. Culture plates were incubated for 18e24 h at37C. The isolated bacteria were identified by conventional
(Becton Dickinson, NY, USA) were used when needed.
Antimicrobial susceptibility testing was performed by the
disk diffusion method according to the guidelines of the
Clinical and Laboratory Standards Institute.13
Covariates including age, gender, body mass index,
diabetes mellitus (including pre-existing or post-transplant
diabetes mellitus), hypertension, hepatitis B, hepatitis C,
immunosuppressant (categorized into tacrolimus-based,
cyclosporine-based, and tacrolimus plus sirolimus), acute
rejection before each UTI, time between transplantation
and each UTI diagnosis, anatomical or functional dysfunc-
tion of urologic system (defined as any abnormality in
urologic evaluations), causative pathogen (categorized into
gram negative bacteria, gram positive bacteria and others),
blood white cell counts, serum C-reaction protein and
baseline serum creatinine level before first UTI (defined as
the averaged values of serum creatinine level collected
twice, 1 month apart before their first UTI) were recorded.
All analyses were performed using SPSS software for
Windows (Version 14.0; SPSS, Chicago, IL, USA). Analyses
were performed with c2 testing for categorical variables
and t test for continuous variables. All variables were
compared in the univariate analysis first and the variables
with P < 0.05 in the univariate analysis, age and gender,
were included in multivariate analysis using the multiple
logistic regression model to determine the relevant risk
factors for concomitant bacteremia and recurrent infec-
tion, respectively. A P value < 0.05 was considered to be
statistically significant.Results
Ninety-nine patients (30 males and 69 females) developed
167 episodes of community-acquired and symptomatic UTI
with a mean follow-up period of 53.5 months. The patients’
characteristics and demographic data are shown in Table 1.
Nine patients died from malignancy and five from sepsis
(all were non-UTI related). The clinical manifestations in
these 167 episodes of UTIs included fever (71%), dysuria/
frequency (25%) and others (4%). Forty-two out of 167
episodes (25%) had concomitant bacteremia but none
developed significant morbidity or mortality. Thirty-six out
of 99 patients (36%) had recurrent infection.
Escherichia coli represented the leading uropathogen
(48%), responsible for nearly half of the community-
acquired UTIs, and had a high resistance rate (64%) to
first-generation cephalosporin (Table 2). All gram negative
bacteria were susceptive to carbapenems (imipenem or
meropenem). Among 81 episodes of E coli infection, 33.3%
and 20.9% of E coli strains were resistant to beta-lactam/
beta-lactamase inhibitors (ampicillin/sulbactam or amoxi-
cillin/clavulanate) and third-generation cephalosporin,
respectively. Furthermore, 41.2% and 17.7% of Klebsiella
spp. strains were resistant to beta-lactam/beta-lactamase
inhibitors and third-generation cephalosporin, respectively.
However, Proteus spp. had a low resistance rate to beta-
lactam/beta-lactamase inhibitors and third-generation
cephalosporin (1.1% and 0%, respectively). Enterococcus
spp. was the most common gram-positive causative
Table 1 Demographic and clinical characteristics in
patients with UTI.
N Z 99
Age at first UTI (years) 53.3  11.1
Gender (male/female) 30/69
Diabetes mellitus 36 (36.4%)
Hypertension 60 (60.6%)
Hepatitis B 10 (10.1%)
Hepatitis C 17 (17.2%)
Immunosuppressive regimen
Cyclosporine based 34 (34.3%)
Tacrolimus based 64 (64.7%)
Tacrolimus and Sirolimus based 1 (1.0%)
Induction therapy* 99 (100.0%)
Time between transplantation and each
UTI diagnosis (median (range); months)
12 (1e82)
Graft loss 8 (8.1%)
Patient death 14 (14.1%)
Follow-up duration (months) 53.5  22.1
Data are presented as mean  SD or n (%), unless otherwise
stated. UTI Z urinary tract infection.
*Induction therapy with basiliximab or daclizumab.
140 S.-W. Wu et al.microorganism and 23% of these strains were resistant to
penicillin. There was no bacterial growth in 11% of the UTI
episodes in our study. Among the causative microorganisms
isolated from patients with bacteremia, gram-negative
bacteria accounted for nearly 90% and E coli was still the
most common pathogen (65%). Among these bacteremic E
coli strains, approximately 60% had resistance to genta-
micin or quinolone.
As shown in Table 3, we found that immunosuppression
with tacrolimus (adjusted odds ratio [AOR] 3.17; PZ 0.011)
and baseline serum creatinine level >1.3 mg/dL before first
UTI (AOR 2.55; P Z 0.045) represented independent risk
factors associated with UTIs with concomitant bacteremia.Table 2 The antibiotic susceptibility of individual microorganis
concomitant bacteremia.
Gram (-) bacteria Number of episodes First cephalospo
A/B group A/B
E. coli 27/54 17 (61%)/35 (64%
Proteus spp. 0/10 NA/2 (20%)
Klebsiella spp. 8/9 4 (50%)/3 (33%)
Enterobacter spp. 0/7 NA/6 (86%)
Pseudomonas spp. 1/9 NA/NA
Acinectobacter spp. 0/1 NA/NA
Morganella spp. 1/1 1 (100%)/1 (100%
Serratia spp. 0/1 NA/1 (100%)
Citrobacter spp. 0/1 NA/0 (0%)
Gram (D) bacteria Penicillin resista
Enterococcus spp. 5/8 0 (0%)/3 (38%)
Staphylococcus spp. 0/3 NA/NA
Data are presented as n (%), unless otherwise stated. G(-) Z gram
applicable; UTI Z urinary tract infection.However, there were no factors that were significantly
associated with recurrent infection (Table 4).
Discussion
UTI is a very common infectious complication among renal
transplant patients but the incidence of UTIs differ widely,
ranging from 43% to 75% in several recent studies.2,4,5,14
This is probably explained by the diversity of the duration
of follow-up, frequency of urine sampling, and most
importantly, the criteria used to define UTI in previous
literature. In our study, we excluded asymptomatic bacte-
riuria from analysis because it might only indicate bacterial
colonization, which would result in overestimating the true
incidence of UTIs. In addition, the treatment for asymp-
tomatic bacteriuria is undetermined at this time because
neither its effect on the risk of a potentially subsequent
UTIs nor its potential harmful effect on graft/patient
survival has been established.15,16
Like previous studies, we found that gram-negative
bacteria remained the most commonly cultured uropath-
ogens (77%) and E coli was responsible for about half of
these. On the other hand, we found that the urine culture
in 11% of UTI episodes revealed no growth of bacteria. Most
previous studies did not include these episodes into their
definition of UTI.4,5,14 However, we believe that episodes
with typical clinical symptoms, consistent urinalysis, and
with resolution of the symptoms after antibiotics therapy
should be regarded as a UTI even if there was no bacterial
growth in the urine culture. The possible reasons to explain
this include previous antibiotic treatment before urine
collection, slow-growing or fastidious bacteria in ordinary
culture media or even non-bacterial uropathogens.
It is not surprising that more than 60% of the E coli
strains in our study had resistance to first-generation
cephalosporin. In Taiwan, the resistance rate of E coli to
first-generation generation cephalosporin among bacter-
emic and non-bacteremic community-acquired UTIs in the
general population was demonstrated to be as high asm causing UTI: episodes with (A group) and without (B group)
rin resistant Gentamycin resistant Quinolone resistant
A/B A/B
) 15 (56%)/9 (17%) 18 (67%)/11 (20%)
NA/1 (10%) NA/1 (10%)
3 (38%)/3 (33%) 1 (13%)/3 (33%)
NA/3 (43%) NA/3 (43%)
0 (0%)/2 (22%) 0 (0%)/2 (22%)
NA/1 (100%) NA/1 (100%)
) 1 (100%)/0 (0%) 0 (0%)/0 (0%)
NA/0 (0%) NA/0 (0%)
NA/0 (0%) NA/0 (0%)
nt Oxacillin resistant
NA/NA
NA/0 (0%)
-negative bacteria; G(þ) Z gram-positive bacteria; NA Z not
Table 3 Demographic and clinical characteristics of the 167 UTI episodes with and without concomitant bacteremia in renal
transplant recipients.
Univariate analysis Multivariate analysis
Bacteremic group
(N Z 42)
Non-bacteremia
group (N Z 125)
AOR (95% CI) P value
Age at first UTI (years) 54.6  10.2 52.8  12.5 1.02 (0.98e1.05) 0.305
Gender
Female 30 (71.4%) 93 (74.4%) 1.55 (0.60e3.98) 0.365
Male 12 (28.6%) 32 (25.6%)
Body mass index (kg/m2) 24.83.8 24.03.7
Cre >1.3 mg/dL before first UTI 17 (40.5%) 31 (24.8%)* 2.55 (1.02e6.36) 0.045y
Immunosuppressant
Tacrolimus based 33 (78.6%) 77 (61.6%)* 3.17 (1.30e7.75) 0.012y
Concomitant steroid use 22 (52.4%) 47 (37.6%)
Diabetes mellitus 17 (40.5%) 37 (29.6%)
Hypertension 25 (59.5%) 67 (53.6%)
Hepatitis B 6 (14.3%) 15 (12.0%)
Hepatitis C 6 (14.3%) 16 (12.8%)
Time between transplantation and
each UTI diagnosis (months)
23.5  26.3 22.5  19.2
Anatomical or functional dysfunction
of urologic system
8 (19.1%) 30 (24.0%)
White cell counts (per uL) 11403  5200 11502  10254
CRP (mg/dL) 8.1  8.3 6.2  5.3
Causative pathogen
Gram negative bacteria 37 (88.1%) 93 (74.4%)* 2.75 (0.96e7.91) 0.060
Gram positive bacteria 5 (11.9%) 32 (25.6%)
Data are shown as meanSD or n (%). AOR Z adjusted odds ratio; CI Z confidence interval; Cre Z serum creatinine level; CRP Z
C-reactive protein; G(-) Z gram-negative bacteria; G(þ) Z gram-positive bacteria; UTI Z urinary tract infection.
*statistically significant in univariate analysis. ystatistically significant in multivariate analysis.
UTI in kidney transplantation 14160%.17 However, in contrast to previous reports and the
non-bacteremic group of our study, approximately 60% of
these bacteremic E coli strains already had resistance to
gentamicin or quinolone in renal transplant patients. This
finding may alert us to modify our policy with regards to
empirical antibiotic therapy for cases of UTI in this special
patient group; that is, to avoid using first-generation
cephalosporin, gentamicin, and quinolone before the
results of the susceptibility test are available, especially
for critical patients. It should be reasonable to categorize
patients with UTIs into two groups: those with or without
ongoing sepsis. For the patients with ongoing sepsis, anti-
biotics like third- or fourth-generation cephalosporin or
carbapenem should be administered as an empiric
antibiotic. The high resistance rate to commonly used
antimicrobials in renal transplant patients can probably
be attributed to repeated infection due to impaired
immunity resulting from multiple underlying comorbidities
and immunosuppressants, perioperative prevention with
first-generation cephalosporin, and post-transplant P
jirovecii pneumonia prevention with trimethoprim-
sulfamethoxazole. Furthermore, frequent exposure to
antibiotics post-transplantation could also be a contributor
because physicians were prone to making a diagnosis ofbacterial infection for renal transplant patients. This may
explain why approximately 60% of the bacteremic E coli
strains in our study had resistance to quinolone. Contrary to
gram-negative bacteria, the problem of antibiotic resis-
tance in gram- positive pathogens seemed to not be as
clinically significant.
In analyzing the risk factors for UTI with concomitant
bacteremia and recurrent UTI in renal transplant recipi-
ents, we found that immunosuppressant with tacrolimus
and baseline serum creatinine level >1.3 mg/dL before first
UTI represented independent risk factors associated with
UTI with concomitant bacteremia. The reasons to explain
these risk factors need to be better defined, but we think
that greater impaired immunity in patients having renal
disease and/or taking stronger immunosuppressants with
tacrolimus could be part of the explanation.18 On the other
hand, we did not find any factors to be significantly asso-
ciated with recurrent infection in our study.
Contrary to the high morbidity and mortality rate in liver
or heart transplant patients with bacteremia,19,20 UTI with
concomitant bacteremia in previous reports did not seem to
directly increase mortality rate; however, one recent
retrospective review study found that UTIs may be associ-
ated with a significantly increased mortality risk in renal
Table 4 Demographic and clinical characteristics of the 99 renal transplant recipients with and without recurrent UTI.
Recurrent (N Z 36) Non-recurrent (N Z 63) P value
Age at first UTI (years) 53.2  11.4 53.3  10.9 0.991
Gender
Male 9 (21.4%) 21 (36.8%) 0.099
Female 33 (78.6%) 36 (63.2%)
Body mass index (kg/m2) 24.1  3.9 24.6  3.8 0.470
Cre >1.3 mg/dL before first UTI 13 (31.0%) 17 (29.8%) 0.904
Immunosuppressant
Tacrolimus based 27 (64.3%) 37 (64.9%) 0.949
Concomitant steroid use 24 (57.1%) 25 (43.9%) 0.191
Diabetes mellitus
Yes 13 (31.0%) 23 (40.4%) 0.337
No 29 (69.0%) 34 (59.6%)
Hypertension
Yes 22 (52.4%) 38 (66.7%) 0.151
No 20 (47.6%) 19 (33.3%)
Hepatitis B
Yes 5 (11.9%) 5 (8.8%) 0.609
No 37 (88.1%) 52 (91.2%)
Hepatitis C
Yes 4 (9.5%) 14 (24.6%) 0.055
No 38 (90.5%) 43 (75.4%)
Time between transplantation and first UTI diagnosis (months) 15.3  17.2 23.5  24.3 0.052
Anatomical or functional dysfunction of urologic system 9 (21.4%) 11 (19.3%) 0.794
Follow-up duration (months) 51.0  22.2 55.4  22.0 0.329
Data are shown as mean  SD or n (%). Cre Z serum creatinine level (mg/dl); CsA Z cyclosporine; UTI Z urinary tract infection.
142 S.-W. Wu et al.transplant patients.5,7e9 In our study, all episodes of UTI
with concomitant bacteremia were treated successfully,
which seemed to imply that UTI even with concomitant
bacteremia itself is indeed a benign medical illness.
However, we think that patient and physician awareness of
potential severe sequelae of infection, loose criteria for
hospitalization, and increasing use of antibiotics such as
third- or fourth-generation cephalosporin or carbapenem in
renal transplant patients could also be contributing factors.
Therefore, not all patients with UTIs will have a benign
course, as was the case for ours, and it is still necessary to
treat these patients properly and individually.
Although this is the first study to our knowledge to
analyze the risk factors for UTI with concomitant bacter-
emia and recurrent UTI in renal transplant recipients, many
potential limitations may exist. Firstly, because this is
a retrospective study, there are many potential inherent
limitations, such as inaccurate written records or incom-
plete data about each antibiotic susceptibility test.
Secondly, in our study, we regarded every recurrent UTI
episode as a re-infection because the interval between
each UTI episode was more than 2 weeks. However, we
could not exclude the possibility of relapse infection, which
could result in repeated counting. Thirdly, to date, the
definition of community-acquired UTI and recurrent UTI has
not clearly been defined. It is therefore difficult to compare
our results with other studies. Finally, even though we tried
to include all relevant data, other unidentified variablesare also probably real risk factors for concomitant bacter-
emia or recurrent UTI.
In conclusion, we found that E coli tends to have resis-
tance to commonly used empirical antibiotics in this
modern era and that patients who use immunosuppressants
with tacrolimus and have baseline serum creatinine level
>1.3 mg/dL before their first UTI have the tendency to
suffer concomitant bacteremia and even sepsis.
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